Navigation Links
Symposium to explore role nanoparticles may play in disease

BETHESDA, Md. (April 2, 2008) Two Mayo Clinic researchers who study the role nanoparticles may play in hardening of the arteries and in the formation of kidney stones, will lead a symposium on how these super-small particles may affect the bodys physiology. The symposium will take place April 8 at the Experimental Biology conference in San Diego.

Nanoparticles are a thousand times smaller than the bacteria, E. coli, but recent advances in microscopy have allowed researchers to watch them interact with cells in the body, said Virginia M. Miller and John C. Lieske of the Mayo Clinic College of Medicine. They will lead the symposium, Using nanotechnology to answer physiological questions.

One of the questions physiologists want to explore is whether nanoparticles can cause diseases such as atherosclerosis, kidney stones, gall stones and periodontal disease. Dr. Lieske is investigating how nano-sized crystals in the kidney can lead to the development of kidney stones. Dr. Miller has been studying the link between atherosclerosis (hardening of the arteries) and nanoparticles which calcify within the arteries.

A fuller audio interview with the researchers is available at

New technology: promise and peril?

Nanotechnology presents intriguing possibilities and some troubling unknowns. The technology is already applied in commercial products as disparate as flame resistant materials and cosmetics. In addition, the technology holds promise in the development of medications that can target precise areas of the body, such as a tumor.

Because of their size, nanoparticles may more easily gain entry to the body, where the longterm effects are unknown. Dr. Miller has found that some nanoparticles cause inflammation when injected into the blood vessels of animals, an early step in the development of atherosclerosis.

Using the latest in microscopy, Dr. Miller has begun to observe nanoparticles from atherosclerotic tissue. She hopes to determine how these particles gain access to cells and whether the interaction eventually leads to cell activation or death leading to calcification.

Kidneys stones start as tiny calcifications which later become larger and eventually develop into kidney stones. Dr. Lieske hypothesizes that the nanoparticle causes the initial calcification. Once that happens, other processes can take place that results in a kidney stone.

It is not yet known where nanoparticles that are implicated in kidney stones and atherosclerosis originate whether our bodies contain them naturally or we obtain them from the environment.

Miller said research should proceed to determine if nanoparticles are safe over the long term. We may not know some of the consequences until further down the road she said.

Dr. Miller and Dr. Lieske will moderate a program on nanotechnology at Experimental Biology. The speakers are Vitaly Vodyanoy of the University of Auburn; Robert Lee of The Ohio State University; Kevin D. Gillis of the University of Missouri-Columbia and Farooq Shiekh of the Mayo Clinic College of Medicine will present at the symposium.


Contact: Christine Guilfoy
American Physiological Society

Related medicine news :

1. NARSADs 5th Annual Mission Possible Symposium Offers Insight to PTSD and Other Mental Illnesses
2. Global Sound Conference Brings Worlds Top Sound Researchers, Technologists and Musicians to Los Angeles for Four Day Symposium
3. Eating Disorders Take Center Stage at iaedp(TM) 2008 Symposium in Orlando, Florida
4. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
5. Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
6. Seal Shield Introduces New Silver Seal Washable, Antimicrobial Mouse at HiMSS Healthcare Symposium
7. AAAS symposium to address significant effects of the male parent in reproductive success
8. Symposium on drug-resistant diseases set for annual AAAS conference
9. Studies on Urgent(R) PC to be Presented at the 2008 Society of Urologic Nurses and Associates Annual Symposium
10. Experts Offer Global Benefits Strategies at Symposium
11. AST to Address New Concept in Organ Allocation at March 13-16 Winter Symposium
Post Your Comments:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology: